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To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin targeted agent vinflunine (VFL)
(320mgm
 2 q 21 days) as second-line chemotherapy in patients with metastatic breast carcinoma (MBC). All patients had disease
progression after anthracycline/taxane (A/T) therapy. They could have received a nonanthracycline adjuvant treatment and
subsequently received a first-line A/T combination for advanced/metastatic disease; or relapsed 46 months after completion of
adjuvant A/T therapy and were subsequently treated with the alternative agent; or relapsed within 6 months from an adjuvant A/T
combination. Objective response was documented in 18 of 60 patients enrolled (RR: 30% (95% confidence interval (CI): 18.9–
43.2%)). Among the responders, seven patients had relapsed during a period of o3 months from taxane-based regimen yielding a
RR of 33.3%. The median duration of response was 4.8 months (95% CI: 4.2–7.2), median progression-free survival was 3.7 months
(95% CI: 2.8–4.2) and median overall survival was 14.3 months (95% CI: 9.2–19.6). The most frequent adverse event was
neutropenia (grade 3 in 28.3% and grade 4 in 36.7% of patients). No febrile neutropenia was observed. Fatigue (grade 3 in 16.7% of
patients) and constipation (grade 3 in 11.7% of patients) were also common; these were non-cumulative and manageable permitting
achievement of a good relative dose intensity of 93.5%. Vinflunine is an active agent with acceptable tolerance in the management of
MBC patients previously treated with (A/T)-based regimens. These encouraging phase II results warrant further investigation of this
novel agent in combination with other active agents in this setting or in earlier stages of disease.
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Anthracyclines, taxanes and vinorelbine are among the most active
agents in the management of advanced breast cancer. Despite the
high level of activity of these agents, metastatic breast cancer
(MBC) is essentially an incurable disease; disease progression
during or after chemotherapy is unavoidable (Hamilton and
Hortobagyi, 2005). No consensus exists for the use of alternative
chemotherapy after anthracycline and taxane failure in MBC; only
capecitabine is currently registered as a standard treatment in this
setting. Therefore, there is a need for new chemotherapy strategies
and new agents in this setting.
Vinflunine (VFL) (Javlor
s, Pierre Fabre Me ´dicament, Boulogne-
Billancourt, France) is a novel microtubule inhibitor agent
obtained by semisynthesis using superacidic chemistry to selec-
tively introduce two fluorine atoms at the 20’ position of
catharanthine moiety of Vinca alkaloid (Fahy et al, 1997). The
diverse actions of VFL on microtubules are likely to produce
different effects on mitotic spindle functions leading to modifica-
tions of cell cycle progression and cell killing (Ngan et al, 2000).
Vinflunine prevents microtubule assembly during mitosis and
induces apoptosis (Kruczynski et al, 1998, 2002). Vinflunine exerts
effects on microtubule dynamic instability suppressing the rate
and extent of microtubule growing events (Ngan et al, 2001). The
affinity profile of VFL shows features which suggest that it will
have greater effects on mitotic rather than axonal tubulin and
so will not cause significant neurotoxicity (Lobert et al, 1998).
Vinflunine showed definite high antitumour activity compared to
vinorelbine in xenografts; against the human MX-1 breast
xenografts, VFL produced an overall growth inhibition of 61%,
whereas vinorelbine did not result in any significant inhibition
(Hill et al, 1999; Kruczynski et al, 1999). Moreover, in the first
Phase I study, two out of three patients with heavily pretreated
MBC achieved partial response (PRs), therefore, VFL was
considered to be a good candidate for further investigation in
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spatients with MBC. Vinflunine treatment every 3 weeks was
considered optimal, based on clinical and pharmacokinetic data
from the three dose schedules evaluated in Phase I trials.
Vinflunine was administered at the beginning of the phase I trials
at 350mgm
 2 in normal saline as a 10-min infusion; after an early
safety analysis this dose was adjusted to 320mgm
 2 which is the
recommended dose for all subsequent patients included in clinical
trials (Bennouna et al, 2003).
MATERIALS AND METHODS
Objectives
This study was a multicentre, international, nonrandomised
Phase II trial, designed to determine the objective response of
intravenous VFL administered once every 3 weeks in patients
with MBC who had received prior anthracycline/taxane (A/T)-
based regimens. Secondary objectives were to assess duration of
response, progression-free survival (PFS) and overall survival
(OS) and to evaluate the treatment-related toxicity. This trial
also included assessment of the pharmacokinetic profile of VFL
and planned to document pharmacokinetic/pharmacodynamic
relationships in a subset of patients.
The protocol and its amendments were submitted to Indepen-
dent Ethics Committees and Health Authorities according to
local requirements. The study was conducted in accordance with
the principles set forth in the Declaration of Helsinki (Somerset
West October 1996) and in compliance with Good Clinical and
Laboratory Practices. Written informed consent was obtained from
each participating patient before enrolment.
Patient selection
Patients were recruited from 15 active centres between March 2002
and September 2003. Patients were required to have histologically
proven breast adenocarcinoma with documented progressive
disease. Eligibility also included either (1) nonanthracycline
adjuvant treatment with at least 6 months disease-free interval
and subsequent treatment with a first-line A/T combination
for advanced/metastatic disease; or (2) disease relapse more than
6 months after completion of adjuvant anthracycline-containing
chemotherapy and subsequent therapy with a taxane-containing
combination as first-line treatment for advanced/metastatic
disease; or (3) relapsed more than 6 months after completion
of adjuvant taxane-containing chemotherapy and subsequently
treated by an anthracycline-containing combination as first-line
treatment for advanced/metastatic disease or (4) relapsed within 6
months from an adjuvant A/T combination therapy. The presence
of at least one bidimensionally measurable lesion, not previously
irradiated, and assessed by CT-scan was required; lesions
were documented by WHO criteria. Patients were required to be
women, aged X18 years with Karnofsky Performance Status (KPS)
X80% and an estimated life expectancy of X12 weeks with
adequate haematological function (absolute neutrophil count
X2.0 10
9l
 1, platelets X100 10
9l
 1), hepatic function (bili-
rubin p1.5 upper normal limit (UNL), transaminases
p2.5 UNL, unless due to liver involvement), renal function,
and a normal electrocardiogram.
Treatment schedule
Vinflunine was administered at the dose of 320mgm
 2 in normal
saline as a 10-min infusion every 21 days. The use of haema-
topoietic growth factors (G-CSF) was allowed for patients with
febrile neutropenia or neutropenic infections according to
institutional standard and practice.
Vinflunine was delayed by 1 or 2 weeks in case of 4grade 2
haematological or nonhaematological toxicity. If febrile neutro-
penia and/or grade 4 neutropenia (o1.0 10
9l
 1) lasting 7 days or
more was observed between two subsequent administrations of
VFL, the dose was to be reduced to 280mgm
 2 from the next cycle
on. If, after a dose reduction, this toxicity was seen again, the dose
was to be further reduced to 250mgm
 2. If at this dose level
the same event recurred, the treatment was to be discontinued.
No dose re-escalation was allowed after dose reduction. In case of
grade 2 mucositis and/or constipation lasting 45 days, or grade
X3 mucositis, and/or constipation of any duration, the VFL dose
was to be reduced to 280mgm
 2 from the next cycle on. If, after
dose reduction, one of these toxicities was seen again, the dose was
to be reduced to 250mgm
 2. If at this dose the event recurred, the
treatment was discontinued.
Tumour response was assessed after the initial two cycles of
therapy. Patients with complete response (CR) or a PR could
continue treatment either until progressive disease (PD), toxicity
or patient preference precluded further therapy; those with stable
disease (SD) received two additional cycles, were assessed a second
time and treatment was continued according to the Investigator’s
opinion. Patients with PD discontinued the treatment.
Baseline and treatment evaluation
Baseline assessments included a detailed medical history;
computed tomography and physical examination (superficial
lymph node or skin nodule). All positive imaging procedures
at study entry had to be repeated every 6 weeks. An assessment
of symptoms was made at study entry and then throughout
treatment. Physical examination and vital signs were assessed on
day one of each 3-week cycle. A complete blood cell count was
taken at baseline and before each cycle of treatment. Additional
samples were planned on day 8 and 15 of each cycle: in case the
ANC was o1.0 10
9l
 1, counts were repeated every 2 days until
recovery to ANC X1.0 10
9l
 1. Transaminases, alkaline phos-
phatases, total bilirubin, LDH, creatinine, electrolytes including
Ca
2þ,N a
þ and K
þ and total protein were assessed at every cycle.
Electrocardiogram was to be performed and recorded before initial
administration and repeated at every cycle.
Response was assessed using the WHO criteria (World
Health Organization, 1979; Green and Weiss, 1992). In order
to be confirmed, CR and PR were to be maintained at 4 weeks.
An independent radiologist reviewed all responses and disease
stabilisations. According to WHO criteria, the duration of response
was calculated for patients with confirmed response (CR or PR)
from the date of registration until the date of documented
progression, start of new anticancer therapy, date of death, loss
to follow-up or last news. The PFS was defined as the time elapsed
from registration until progression, death, loss to follow-up or last
news; OS was defined as the time elapsed from registration date to
death, loss to follow-up or last news. Safety analyses were
performed in patients having received at least one dose of study
treatment according to the NCI CTC Version 2.0 grading.
Pharmacokinetic sampling
Pharmacokinetic sampling of VFL was optional and was studied
during cycles 1 and 2. Three blood samples were collected between
T0 and T16 (initial 16h). The exact time of sampling was randomly
assigned to the investigator centres in order to give wide coverage
of the time interval. Vinflunine and 4-O-deacetylvinflunine (DVFL)
blood concentrations were quantified using a HPLC method with
UV detection.
Statistical analysis
A total of sample size of 55 evaluable patients was calculated using
a one-sample multiple testing procedure (Fleming, 1982) and was
based on a null hypothesis for the true response rate of 15% and an
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salternative hypothesis of 30% with a type I error alpha of 5% and
type II error beta of o20%. Continuous data were summarised
using median, minimum and maximum values. Categorical data
were presented in contingency tables with frequencies and
percentages. Confidence intervals (CI) were calculated at the 95%
level. Time dependent parameters were analysed using the
Kaplan–Maier method and 95% CI of the median was reported.
Efficacy analyses were performed on the intent to treat (ITT)
and evaluable populations. The other efficacy parameters were
duration of response, PFS and OS. A subgroup analysis of response
was performed according to the time elapsed between the end of
treatment with the taxane-containing regimen and progression.
Safety analyses were performed in patients having received at least
one dose of study treatment for haematological and nonhaema-
tological adverse events.
All statistical analyses were performed with the 8.2 version of
SAS
s (SAS Institute Inc., Cary, NC USA) for Windows
s .
RESULTS
Sixty patients with advanced or metastatic carcinoma of the breast
were enrolled. Among these patients, five were not eligible but
considered for the study evaluation on an ITT basis (one with no
target lesions, one without prior chemotherapy for advanced
disease, one patient with more than one prior line of chemo-
therapy, one received cisplatin in the first-line setting but received
A/T in the adjuvant setting; one patient assessed without imaging
procedures).
Demographic features of the patients are summarised in Tables
1 and 2. All patients enrolled had received prior A/T-based
chemotherapy before study entry in neoadjuvant intent for one
patient (1.7%), adjuvant intent for two patients (3.3%) and as
first-line treatment for advanced disease in 57 patients (95.0%)
(Tables 3 and 4).
The median time elapsed between diagnosis of invasive breast
cancer and inclusion in the trial was 4.2 years (range: 0.4–17.3).
The median progression-free interval after taxane-based regimens
was 4.8 months (range: 0–29).
The first stage required five of 30 patients to have an objective
response (CRþPR). As nine of the first 30 patients (30%) met this
criterion, the study was opened to the second stage and an
additional 25 patients were enrolled.
Among the 60 patients included, 18, achieved a tumour objective
response of 30% (95% CI: 18.9–43.2%]), and 21 had a stable
disease of 35.0% (Table 5).
Of note, 14 of the responders had visceral involvement
(45 patients had visceral involvement at baseline). Five patients
could not be evaluated for response but were kept in the
denominator for the purpose of the calculation of the response
rate: three patients received a single cycle of treatment (one patient
due to drug-related toxicity, one case of patient’s refusal to
continue and one case due to nondrug-related adverse event),
one unevaluable due to the fact that CT scan slides were
not comparable over the different tumour assessments, and
one patient with liver haemangioma as selected target lesion
(after panel review).
It is noteworthy that among the 18 responders seven had
experienced previous tumour relapse o3 months, achieving a RR
of 33.3% (95% CI: 14.6–57.0) in this group.
The median duration of response was 4.8 months (95% CI:
4.2–7.2). The median duration of stable disease was estimated at
Table 1 Demographic data
Demographic data ITT patients
Age (years) (N¼60)
Median 55.2
Range (33.0–75.8)
Karnofsky performance status (%) N¼60 (%)
100 18 (30.0)
90 19 (31.7)
80 20 (33.3)
70 3 (5.0)
No. of organs involved
1 16 (26.7)
2 23 (38.3)
X3 21 (35.0)
Organs involved
Liver 40 (66.7)
Lung 19 (31.7)
Lymph nodes 24 (40.0)
Pleural effusion 13 (21.7)
Soft tissue 8 (13.3)
Skin 8 (13.3)
Others 6 (10.0)
Breast 1 (1.7)
Bone 21 (35.0)
Abbreviation: ITT¼intent to treat.
Table 2 Hormonal receptors at diagnosis
ER
Positive Negative Unknown or missing Total
PR
Positive 22 2 0 24
Negative 7 13 0 20
Unknown or missing 9 0 7 16
Total 38 15 7 60
Abbreviation: PR¼partial response.
Table 3 Prior chemotherapy
(N¼60) %
Intent of prior chemotherapy
Neoadjuvant 1
a 1.7
Adjuvant 2
a 3.3
Neoadjuvant+metastatic 5 8.3
Adjuvant+metastatic 35 58.3
Neoadjuvant+adjuvant+metastatic 2 3.3
Metastatic 15 25
aTwo patients were enrolled into the study after adjuvant or neoadjuvant failure;
relapsing within 6 months of last administration of neoadjuvant anthracycline and
taxane combination.
Table 4 Previous chemotherapy for advanced disease
N (%) %
Class of chemotherapy
Taxane-anthracyclines 31
a,b 51.6
Taxane single agent 21 35.0
Taxane+other 3 5.0
Anthracycline based 4 6.7
Cisplatin 1 1.7
aTwo patients were enrolled into the study after adjuvant or neoadjuvant failure;
relapsing within 6 months of last administration of neoadjuvant anthracycline and
taxane combination.
bOne patient having progressed 46 months after adjuvant
treatment (considered a major protocol deviation).
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s4.1 months (95% CI: 3.3–5.7). Median PFS was 3.7 months (95%
CI: 2.8–4.2) (Figure 1), and the median OS was estimated at 14.3
months (95% CI: 9.2–9.6) (Figure 2).
Karnofsky Performance Status (KPS) was recorded for each
patient at baseline and before each treatment cycle during the
study (every 3 weeks). During treatment the KPS stayed the same
or improved in 43 out of 60 patients; only two patients experienced
a decrease of 20% in KPS score.
Pharmacokinetic results
The number of patients evaluable for pharmacokinetics was 17 and
15 in cycles 1 and 2, respectively. All patients were first treated at
the dose of 320mgm
 2, seven of them had a dose reduction to
280mgm
 2 in cycle 2; results are shown in Table 6.
The mean total clearance and the range of the individual
values were comparable between cycles 1 and 2. The intraindivi-
dual variability of Cltot was low between cycles 1 and 2: variability
values were all o19% and 11 out 15 values were o10%. No
statistically significant difference in Cltot (P¼0.871) and T1/2 z
(P¼0.928), was observed between cycles 1 and 2 using a paired
t-test. The four patients who experienced grade 3 and 4 SAEs, did
not show any VFL blood overexposure.
Safety evaluation
All 60 patients were evaluable for safety. The total number of
cycles administered was 292; (median 5 cycles; (range 1–12)). The
median relative dose intensity was 93.5%. Twenty-two out of the 60
patients (36.7, 9.9% of cycles) had dose reductions.
Twenty-four patients (40%) experienced grade 3/4 leucopenia
during the study (15.2% of cycles). Grade 3/4 neutropenia
occurred in 65% of patients (36.2% of cycles) (Table 7). The
median nadir value for leucocytes and neutrophils was 2.3 10
9l
 1
and 0.7 10
9l
 1, respectively. The median cycle at which both
leucocyte and neutrophil nadirs occurred was the second cycle
of treatment (on days 8 and 11, respectively). The median dura-
tion of leucocyte and neutrophil nadir was 7 days. No febrile
neutropenia was observed. Grade 3–4 neutropenia complicated
with infection was observed in 8.3% of patients (1.7% of cycles).
Only 3.1% of patients received growth factor support.
Anaemia was rarely severe; only 5.0% of patients developed
grade 3 toxicity (1.0% of cycles). The incidence of thrombocyto-
penia was low, only one out of 60 patients developed grade 3 (0.3%
of cycles).
The incidence (Table 5) of severe nausea and vomiting was
very low: only 8.3% of patients experienced grade 3 nausea and
only 6.7% of patients experienced grade 3 vomiting. The overall
incidence of constipation was 63.3%; 16 patients (26.7%) requiring
stool softeners or dietary modifications (grade 1), four (6.7%)
requiring laxatives (grade 2) and seven patients (11.7%) experi-
enced grade 3 constipation (2.7% of cycles) requiring enema. Ileus
was reported in two patients, this event occurred after the first
administration and recovered completely allowing continuation of
treatment at 280mgm
 2.
Grade 3 or 4 myalgia was observed in only 3.4% of patients
(0.6 % of cycles). Grade 3 fatigue was experienced by 16.7% of
patients (4.1% of cycles). No grade 3–4 peripheral neuropathy
was experienced. Among the 36 patients receiving the drug via
peripheral veins, 13 developed mild injection site reactions of
grade 1 or 2; no grade 3 reactions were observed. Grade 1–2
alopecia was seen in 35% of patients. No clinically significant
alterations in renal or hepatic function were observed. No
treatment-related deaths were reported.
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Figure 1 Progression-free survival.
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Figure 2 Overall survival.
Table 5 WHO overall response rates
Overall response ITT N¼60 (%)
PR 18 (30.0)
95% CI (18.9–43.2)
Stable disease 21 (35.0)
Nonevaluable 5 (8.3)
Disease progression 16 (26.7)
Abbreviations: CI¼confidence interval; PR¼partial response; ITT¼intent to treat;
WHO¼World Health Organization.
Table 6 Main mean (s.d.) blood pharmacokinetic parameters of
vinflunine
Cycle 2 (n¼15 patients)
Cycle 1 (n¼17 patients) 320mgm
 2: 8 patients
Parameters 320mgm
 2 280mgm
 2: 7 patients
Cltot (L.h
 1) 41.7 (12.1) 42.5 (14.4)
T1/2 z (h) 46.6 (7.58) 46.4 (7.73)
Vd (L) 2749 (269) 2770 (306)
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sDISCUSSION
The data of our study support the hypothesis that VFL is an active
and well-tolerated agent for the treatment of patients with MBC.
Specifically, these data were derived in the setting of prior therapy
with anthracycline and taxane, a situation that is increasingly
common in breast cancer management. The value of identifying
novel agents for the management of MBC patients previously
treated with anthracyclines and taxanes is underscored by the fact
that in the eligible patient population only capecitabine is
currently registered as a standard treatment in this setting.
The first trial to assess capecitabine was conducted in 162
patients with paclitaxel-refractory MBC; the ORR in this popula-
tion was 20%, median time to progression (TTP) 3 months, and OS
12.6 months (Blum et al, 1999). An ORR of 15% was obtained in
another clinical study (136 patients), with a median TTP and OS of
3.5 months and 10.1 months was observed respectively; the median
interval between the last taxane-containing therapy and start of
capecitabine treatment in this study was 4.4 months and 17% of
patients discontinued the study drug due to drug-related adverse
events, mainly hand-foot syndrome (Reichardt et al, 2003).
Most recently, in a study of 126 patients with MBC treated
with capecitabine after two or three prior chemotherapies
including an anthracycline and a taxane, the ORR was 28.0% and
the TTP was 4.9 months (95% CI: 4.0–6.4 months) with a median
OS of 15.2 months (95% CI: 13.5–19.6 months) (Fumoleau et al,
2004). One single-agent study with gemcitabine at 1200mgm
 2
days 1, 8 and 15 q 4 weeks, failed to demonstrate objective
response in 23 patients (Smorenburg et al, 2001). Clearly other
active agents are needed.
A phase II trial of vinorelbine in 40 patients with paclitaxel-
refractory MBC demonstrated a median time to progression of 3
months and a median survival of 8 months with an objective
response rate of 25% (Livingston et al, 1997). Moderate activity
has been observed with irinotecan and pemetrexed yielding ORRs
of 14–26% and 10–26%, respectively, in patients with MBC after
anthracycline and/ or taxane exposure (Calvert, 2003; Heinemann,
2003; Perez et al, 2004). In a phase II trial with ixabepilone, 37
women with metastatic and locally advanced breast cancer who
had received paclitaxel and/or docetaxel as prior neoadjuvant,
adjuvant or metastatic therapy, the ORR was 22% and median
duration of response 3.8 months; the median PFS was established
at 2.8 months (Low et al, 2005).
The present study confirms that VFL is an active and tolerable
treatment for the management of MBC previously treated
with anthracycline and taxane-based regimens. The overall
response rate of 30% and the response rate of 33% in patients
who had developed tumour relapse less than 3 months after
a taxane containing regimen, place VFL among the most active
drugs in this setting. This is supported by the median OS estimated
at 14.3 months. Although VFL was associated with some severe
toxicity in the form of myelosuppression and constipation
these adverse events were predictable, reversible, noncumulative
and manageable.
Table 7 Adverse events according to NCI CTC (version 2.0)
N¼60 patients N¼288
a cycles
Adverse events (%) Overall incidence Grade 3 Grade 4 Overall incidence Grade 3 Grade 4
Anaemia 50 (83.3) 3 (5.0) 0 180 (62.5) 3 (1.0) 0
Leucopenia 55 (91.7) 21 (35.0) 3 (5.0) 207 (71.9) 41 (14.2) 3 (1.0)
Neutropenia 55 (91.7) 17 (28.3) 22 (36.7) 211 (73.3) 69 (24.0) 35 (12.2)
Thrombocytopenia 30 (50.0) 1 (1.7) 0 56 (19.4) 1 (0.3) 0
Febrile neutropenia 0 0 0 0 0 0
Infection
Infection+G 3/4 neutropenia 5 (8.3) 3 (5.0) 1 (1.7) 5 (1.7) 3 (1.0) 1 (0.3)
Infection without neutropenia 3 (5.0) 0 0 4(1.4) 0 0
Gastrointestinal
Nausea 35 (58.3) 5 (8.3) 0 79 (27.1) 5 (1.7) 0
Vomiting 28 (46.7) 4 (6.7) 0 54 (18.5) 5 (1.7) 0
Constipation 38 (63.3) 7 (11.7) 0 89 (30.5) 8 (2.7) 0
Diarrhoea 8 (13.3) 1 (1.7) 0 10 (3.4) 1 (0.3) 0
Stomatitis 33 (55.0) 1 (1.7) 0 54 (18.5) 1 (0.3) 0
Dermatological
Alopecia 21 (35.0) NA NA NA NA NA
Injection site reaction 13 (36.1) 0 NA 24 (21.8) 0 NA
Neurology
Ileus 2 (3.3) 2 (3.3) 0 2 (0.7) 2 (0.7) 0
Neuropathy sensory 8 (13.3) 0 0 22 (7.5) 0 0
Pain
Abdominal pain 27 (45.0) 7 (11.7) 0 45 (15.4) 8 (2.7) 0
Arthralgia 14 (23.3) 1 (1.7) 0 30 (10.3) 1 (0.3) 0
Myalgia 14 (23.3) 1 (1.7) 1 (1.7) 21 (7.2) 1 (0.3) 1 (0.3)
Jaw pain 8 (13.3) 2 (3.3) 0 30 (10.3) 9 (3.1) 0
Flu-like symptoms
Fatigue 49 (81.7) 10 (16.7) 0 147 (50.3) 12 (4.1) 0
Fever without neutropenia 6 (10.0) 0 0 6 (2.1) 0 0
aFour cycles were not assessed for haematological parameters due to missing data.
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sIn conclusion, the present study demonstrates that VFL has
clinically relevant activity with acceptable toxicity in the treatment
of patients with advanced breast cancer who have failed prior A/T
containing regimens. These results warrant further investigation in
phase III trials of MBC either as monotherapy or in combination
with other agents in first-line treatment.
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